Radius Health (RDUS) Reports Narrower Q4 Loss Than Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Radius Health Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
March 10, 2015 7:00 AM EDTManagement to host conference call today at 7:30 am ET
WALTHAM, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq: RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, reported its financial results for the fourth quarter and full year ended December 31, 2014, and provided recent corporate highlights. As of December 31, 2014, Radius had cash, cash equivalents and marketable securities of $105.3 million, and in a public offering on January 28, 2015 raised an additional $158.6 million, net of underwriting... More
